Patient autoantibody characteristics
| P1 | P2 | |
| ANA (titre) | Positive (1/640) | Positive (1/320) |
| Description | Homogenous and chromosomal straining pattern in the nucleus, cytoplasm negative | Homogenous and chromosomal straining pattern in the nucleus, cytoplasm negative |
| Anti-DNA Farr (cut-off) | 7.1 IU/mL (≥7.0) | 9.1 IU/mL (≥7.0) |
| CTD screening* | Negative | Negative |
| p-ANCA (titre) | 1/320 | 1/160 |
| MPO-ANCA | Negative | Negative |
| PR3-ANCA | Negative | Negative |
| Thyroglobulin Ab (cut-off) | 385 IU/mL (≥115) | 139 IU/mL (≥115) |
| Thyroid peroxidase Ab (cut-off) | 63 IU/mL (≥34) | 154 IU/mL (≥34) |
| IgG (normal range) | 15.9 g/L (5.58–12.54) | 17.5 g/L (5.58–12.54) |
| HLA-B27 | Positive | Positive |
| HLA-B51 | Negative | Negative |
*CTD (connective tissue disease) screening covers SSB/La, U1-RNP, RNP-70, SmD, Scl-70, Jo-1 and Ro60 antigens.
ANA, anti-nuclear antibodies; ANCA, anti-neutrophil cytoplasmic antibodies; CTD, connective tissue disease; HLA-B, human leucocyte antigen; MPO-ANCA, myeloperoxydase anti-neutrophil cytoplasmic antibodies; PR3-ANCA, proteinase 3 anti-neutrophil cytoplasmic antibodies.